Insulet Lifts Outlook After Strong Quarter
The diabetes device maker reported third-quarter revenue of $842 million and raised the low end of its 2026 revenue forecast.
Updated on Nov. 4, 2026 in Diabetes
Insulet reported third-quarter 2026 revenue of $842 million, up 19.2% year over year, and adjusted earnings of $1.99 per share, beating the Wall Street estimate of $1.59. The company also raised the lower end of its 2026 revenue forecast to $3.277 billion and approved a $1 billion share repurchase program.
Why it matters
The results point to continued demand for Omnipod insulin pump systems among people with diabetes in the United States and abroad. The buyback and raised outlook signal management confidence even as the company faces a Class I recall classification for an Omnipod pod.
Insulet's U.S. Omnipod revenue rose 14.7% to $570.4 million, while international revenue grew 31.7% to $266.2 million, with Drug Delivery revenue falling 22.7% to $5.5 million. The FDA classified an Omnipod pod recall as Class I after reports linked to 24 serious injuries, and the source does not describe the recall's effect on sales.
The players
Insulet
Insulet is a medical device company that makes the Omnipod tubeless insulin delivery system for people with diabetes.
U.S. Food and Drug Administration
The FDA is the U.S. federal agency responsible for regulating medical devices, including the classification of product recalls.
The details
Insulet credited growth to Omnipod, with total Omnipod revenue reaching $836.6 million in the quarter. The company completed the full U.S. market release of Omnipod Discover in October and finished expanding its U.S. sales force, and it expects to launch Omnipod 6 in 2027 while anticipating slower revenue growth that year.
Timeline
October 2026: Full U.S. market release of Omnipod Discover completed.
Third quarter 2026: Insulet reported results that beat expectations.
Fourth quarter 2026: About $400 million expected to go toward share buybacks.
2027: Omnipod 6 launch expected and revenue growth expected to slow.
Market Landscape
Insulet's Omnipod platform, which uses a tubeless pod rather than a tethered pump, continues to drive the company's growth, with total Omnipod revenue up 19.7% this quarter. The FDA's Class I classification of an Omnipod pod recall adds a regulatory dimension to that growth trajectory.
For people using Omnipod, the company's expanded U.S. and international reach and the planned Omnipod 6 launch in 2027 point to continued product availability. The Class I recall classification is a reminder that device users should follow any notices about the pods they use.
The takeaway
Insulet's results show strong demand for tubeless insulin delivery, but a recall classification is a reminder for users to monitor their device notices. Anyone with questions about their pod should contact their healthcare provider.
What happens next
Insulet expects to launch Omnipod 6 in 2027 and to allocate approximately $400 million toward buybacks in the fourth quarter of 2026.
Further reading
For more on the condition behind these devices, see Diabetes.
Source note: This article includes information reported by Benzinga.
